hereditary angioedema

FDA stop sign

Biotech

FDA's 'heavy workload' blamed for delaying KalVista's PDUFA date

KalVista has become the latest biotech to face delays to FDA decision-making, as the agency blames a “heavy workload” for pushing back a PDUFA date.

James Waldron Jun 16, 2025 4:33am

Three blocks displaying from left to right a person a handshake and another person

KalVista sells Japanese rights for HAE drug to Kaken

Apr 8, 2025 8:35am

Liver disease

Poseida gene therapy reduces kallikrein protein levels in mice

Oct 24, 2024 1:20pm

CRISPR Therapeutics

Intellia links in vivo CRISPR therapy to 81% drop in HAE attacks

Oct 24, 2024 8:55am

chop down cut tree chainsaw ax

Pharming uproots angioedema gene therapy collab with Orchard

May 8, 2024 6:15am

city sky stars sunset

With new data in hand, Astria makes ph. 3 wish on shooting star

Mar 25, 2024 10:46am